Bio-Techne Corporation (TECH) Stock: Price, Forecast & Analyst Target
Bio-Techne Corporation (TECH) — MoonshotScore 92/100 (Exceptional band), calculated Nov 18, 2026. Price $72.70 (-0.07%), as of the Nov 19, 2026 trading session; market cap $11.4B. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 32.47× (cash as of Sep 30, 2026) · expected results Feb 3, 2027
Bio-Techne Corporation · TECH · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Bio-Techne supplies the reagents, instruments and analytical workflows used by research, diagnostic and bioprocessing laboratories; it is a life-science tools vendor, not a drug developer. Consumables generate most sales, so laboratory activity and repeat reagent demand matter more than the biotechnology label suggests. The case depends on whether renewed quarterly growth can become durable while current profitability and cash conversion hold against a demanding valuation.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Bio-Techne (TECH)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a fortress balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $287M (Q1 FY2026, quarter ended Sep 2025)
- EPS beat 4 of the last 8 reports
- Altman Z 16.12 · Piotroski F 6
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 90 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional | |
| 92 | Exceptional | |
| 92 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $72.70 | |
| Change on the day | -0.07% | |
| 52-week range | $43.20–$72.88 | |
| Market capitalisation | $11.4B | — |
| Price / earnings (trailing) | 66.03 | |
| Shares traded on the day | 3.31M | |
| Beta (volatility vs the S&P 500) | 1.27 | |
| Dividends per share (last 12 months) | $0.40 | |
| Dividend yield (last 12 months) | 0.55% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · in line with the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Events are in date order; the spacing is not a duration scale. Estimated dates can change.
Other perspectives
Council score for Bio-Techne (TECH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Bio-Techne (TECH), and what does it report?
Short answer · as of
Protein Sciences sells cytokines, growth factors, antibodies, cell-selection products and protein-analysis systems.
Research dated 2026-09-13.
Diagnostics and Spatial Biology supplies controls, calibrators, assays and tissue-analysis products for research and clinical workflows.
Reported revenue combines consumables, instruments and royalties, with consumables overwhelmingly dominant. The numbers therefore measure demand across laboratory workflows rather than the commercial progress of a proprietary therapy.
What do the latest results show for Bio-Techne (TECH)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $287M.
Research dated 2026-09-13.
Latest-quarter revenue rose sequentially and from the comparable period, while gross profit, operating income and net income remained well above the loss-making comparison. Annual sales were essentially flat, however, even as annual net income rebounded sharply from its depressed base.
Consumable-heavy sales make laboratory usage and reagent replenishment the underlying volume mechanism. The latest release exceeded the revenue expectation and broadly matched the earnings expectation, but recent earnings history has alternated between beats and misses rather than establishing a clean pattern.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $299.71M Sep 30, 2026
- Latest quarter · R&D
- $26.34M Sep 30, 2026
- Latest quarter · SG&A
- $133.68M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $36.60M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $299.71M | $26.34M | $133.68M | $36.60M |
| Jun 30, 2026 | $321.19M | $23.95M | $113.17M | $74.28M |
| Mar 31, 2026 | $311.42M | $23.45M | $109.34M | $75.50M |
| Dec 31, 2025 | $295.88M | $23.13M | $113.69M | $54.46M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $299.71M Nov 6, 2026
- Latest report · revenue estimate
- $292.60M Nov 6, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 6, 2026
- Latest report · EPS vs estimate
- In line Nov 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 6, 2026 | $299.71M | $292.60M | $0.4400 | $0.4400 |
| Aug 12, 2026 | $321.19M | $314.63M | $0.5200 | $0.5190 |
| May 6, 2026 | $311.42M | $316.11M | $0.5300 | $0.5500 |
| Feb 4, 2026 | $295.88M | $290.47M | $0.4600 | $0.4300 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $287M | $38M | $0.24 (diluted) |
| Q2 FY2026 | $296M | $38M | $0.24 (diluted) |
| Q3 FY2026 | $311M | $51M | $0.32 (diluted) |
| Q4 FY2026 | $321M | $55M | $0.36 (diluted) |
What are the financial strengths and risks for Bio-Techne (TECH)?
Short answer
Cash and short-term investments were $351.13M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $73.11M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow stayed positive across the reported quarterly series and strengthened through the latest periods, while capital expenditure remained modest beside cash generation. Cash and short-term investments also rebuilt steadily from the recent low.
Cash plus reported investments exceeds total debt, although cash and short-term investments alone sits slightly below debt and the long-term investments are not classified. Liquidity and distress screens are strong, but valuation multiples remain elevated and cash-flow yield remains modest, leaving little room for a renewed earnings setback.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $73.11M Sep 30, 2026
- Previous quarter · operating cash flow
- $95.42M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $73.11M | −$5.92M |
| Jun 30, 2026 | $95.42M | −$8.48M |
| Mar 31, 2026 | $86.66M | −$9.09M |
| Dec 31, 2025 | $82.41M | −$5.92M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Bio-Techne (TECH)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027.
Research dated 2026-09-13.
Watch whether consumable demand preserves the recent sequential revenue progression, whether gross profit converts into operating income, and whether operating cash flow continues to rebuild cash. Instrument sales matter less to current scale, but placements can support future use of associated assays and reagents.
The upcoming earnings expectation implies revenue below the latest reported level, while longer-range estimates assume renewed expansion. Recent analyst actions moved broadly toward neutral stances, making execution against that growth path more informative than the labels themselves.
What the records here don't tell us
- The newest quarter held here (Q1 FY2026) was filed Nov 5, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Bio-Techne compare with its peers?
Short answer
Bio-Techne's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Bio-Techne differs from therapy-focused biotechnology companies because customers buy research inputs, diagnostic controls, analytical instruments and workflow services rather than exposure to a clinical pipeline. Its economics are anchored in consumables, with instruments and royalties providing smaller revenue streams.
That mix can create repeat purchasing around established laboratory workflows, while still tying demand to research activity, diagnostic testing and bioprocessing workloads. The combination of high gross margin, strong liquidity and a rich sales multiple makes durability of consumable demand especially important.
| Company | Price | Market value | Score |
|---|---|---|---|
| $65.83 Nov 19, 2026 | $16.1B | 98 5-pillar Nov 18, 2026 | |
| $95.05 Nov 18, 2026 | $7.47B | 98 5-pillar Nov 18, 2026 | |
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| Bio-Techne (TECH) — this page | $72.70 | $11.4B | 92 |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $149.40 Nov 18, 2026 | $20.0B | 72 5-pillar Nov 18, 2026 | |
| $95.74 Nov 18, 2026 | $6.49B | 67 5-pillar Nov 18, 2026 | |
| $247.77 Nov 18, 2026 | $15.9B | 40 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $65.00 – $73.00
- Consensus target
- $71.67
- Median target
- $73.00
Consensus record · Captured .
Measured against a quoted price of $72.70 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 1, 2026
- Transactions
- 60
- Identified insiders
- 13
- Purchases
- 0
- Sales
- 0
- Other transactions
- 60
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 99.7% Period end Sep 30, 2026
- Reporting holders
- 599 Period end Sep 30, 2026
- Previous quarter · holders
- 617 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 14,250,400 |
| Vanguard Capital Management LLC | 10,250,628 |
| Hbk Investments L P | 7,732,128 |
| Vanguard Portfolio Management LLC | 6,348,862 |
| Fil Ltd | 6,272,729 |
Tracked investors
Which of the 16 named investors we follow held TECH in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0% | $0 | Sold out (was $1.89M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Bio-Techne (TECH)?
Common Questions About TECH (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is Bio-Techne better understood as a laboratory supplier than a drug developer?
Bio-Techne sells reagents, assays, controls and analytical instruments used by researchers, diagnostic laboratories and bioprocessing customers. Its revenue reflects customer workflow activity rather than approval or sales of a proprietary medicine.
How do Protein Sciences and Diagnostics and Spatial Biology differ at Bio-Techne?
Protein Sciences centers on biological reagents, cell-selection products and protein-analysis workflows. Diagnostics and Spatial Biology focuses on controls, calibrators, diagnostic assays and tissue-based analysis products for research and clinical applications.
Why do Bio-Techne instruments matter when consumables dominate sales?
Instruments embed Bio-Techne within protein and tissue-analysis workflows, while assays and reagents account for most reported sales. Instrument adoption can therefore matter through the consumables used around those workflows, even though instrument revenue is much smaller.
Can Bio-Techne fund reagent development and its dividend from operating cash?
Operating cash flow remained positive throughout the reported quarterly series and recently strengthened, while capital spending stayed comparatively modest. Research expense and dividends remain continuing uses of that internally generated cash, but current liquidity provides substantial flexibility.
What is the TECH stock price today?
The last price recorded for Bio-Techne Corporation (TECH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TECH price target?
The analyst consensus price target for Bio-Techne Corporation (TECH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 82 figures on this page — 1 from SEC filings and earnings calls, 72 from Financial Modeling Prep (FMP), 3 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com